These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 20415859)

  • 21. Peptide Immunotherapy for Type 1 Diabetes-Clinical Advances.
    Smith EL; Peakman M
    Front Immunol; 2018; 9():392. PubMed ID: 29541078
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Autoimmune Diabetes: An Overview of Experimental Models and Novel Therapeutics.
    You S; Chatenoud L
    Methods Mol Biol; 2016; 1371():117-42. PubMed ID: 26530798
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: controversial aspects of the 'hygiene hypothesis'.
    Matricardi PM
    Clin Exp Immunol; 2010 Apr; 160(1):98-105. PubMed ID: 20415858
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Operational immune tolerance towards transplanted allogeneic pancreatic islets in mice and a non-human primate.
    Abdulreda MH; Berman DM; Shishido A; Martin C; Hossameldin M; Tschiggfrie A; Hernandez LF; Hernandez A; Ricordi C; Parel JM; Jankowska-Gan E; Burlingham WJ; Arrieta-Quintero EA; Perez VL; Kenyon NS; Berggren PO
    Diabetologia; 2019 May; 62(5):811-821. PubMed ID: 30701283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Are B cells a potential target for therapeutic intervention in the classical T cell-mediated autoimmune disease type 1 diabetes?
    Wållberg M; Green EA
    Inflamm Allergy Drug Targets; 2009 Jun; 8(2):130-8. PubMed ID: 19530995
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune and cell therapy in type 1 diabetes: too little too late?
    Gillard P; Mathieu C
    Expert Opin Biol Ther; 2011 May; 11(5):609-21. PubMed ID: 21406028
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determining Antigen Specificity of Human Islet Infiltrating T Cells in Type 1 Diabetes.
    Nakayama M; Michels AW
    Front Immunol; 2019; 10():365. PubMed ID: 30906293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diabetes technology and treatments in the paediatric age group.
    Shalitin S; Peter Chase H
    Int J Clin Pract Suppl; 2011 Feb; (170):76-82. PubMed ID: 21323816
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Innovative immune-based therapeutic approaches for the treatment of type 1 diabetes mellitus.
    Eldor R; Cohen IR; Raz I
    Int Rev Immunol; 2005; 24(5-6):327-39. PubMed ID: 16318985
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autoreactive T cell responses in insulin-dependent (Type 1) diabetes mellitus. Report of the first international workshop for standardization of T cell assays.
    Roep BO; Atkinson MA; van Endert PM; Gottlieb PA; Wilson SB; Sachs JA
    J Autoimmun; 1999 Sep; 13(2):267-82. PubMed ID: 10479395
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antigen-specific induction of regulatory T cells for type 1 diabetes therapy.
    Filippi C; Bresson D; von Herrath M
    Int Rev Immunol; 2005; 24(5-6):341-60. PubMed ID: 16318986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rational development of antigen-specific therapies for type 1 diabetes.
    Fousteri G; Bresson D; von Herrath M
    Adv Exp Med Biol; 2007; 601():313-9. PubMed ID: 17713020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The 'Hygiene hypothesis' and the sharp gradient in the incidence of autoimmune and allergic diseases between Russian Karelia and Finland.
    Kondrashova A; Seiskari T; Ilonen J; Knip M; Hyöty H
    APMIS; 2013 Jun; 121(6):478-93. PubMed ID: 23127244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Parameters influencing antigen-specific immunotherapy for type 1 diabetes.
    Wang B; Tisch R
    Immunol Res; 2008; 41(3):175-87. PubMed ID: 18543112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T cells in type 1 diabetes: Instructors, regulators and effectors: A comprehensive review.
    Gomez-Tourino I; Arif S; Eichmann M; Peakman M
    J Autoimmun; 2016 Jan; 66():7-16. PubMed ID: 26343335
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stem cell-based immunomodulation in type 1 diabetes: beyond the regenerative approach.
    Longoni B; Mosca F
    Curr Pharm Des; 2011; 17(29):3229-42. PubMed ID: 21864271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insights into the pathogenesis of type 1 diabetes: a hint for novel immunospecific therapies.
    Casares S; Brumeanu TD
    Curr Mol Med; 2001 Jul; 1(3):357-78. PubMed ID: 11899083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cellular and molecular pathogenic mechanisms of insulin-dependent diabetes mellitus.
    Yoon JW; Jun HS
    Ann N Y Acad Sci; 2001 Apr; 928():200-11. PubMed ID: 11795511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The potential role of dendritic cells in the therapy of Type 1 diabetes.
    Lee CN; Lew AM; Wu L
    Immunotherapy; 2013 Jun; 5(6):591-606. PubMed ID: 23725283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients.
    Rosenzwajg M; Churlaud G; Mallone R; Six A; Dérian N; Chaara W; Lorenzon R; Long SA; Buckner JH; Afonso G; Pham HP; Hartemann A; Yu A; Pugliese A; Malek TR; Klatzmann D
    J Autoimmun; 2015 Apr; 58():48-58. PubMed ID: 25634360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.